Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVDLNASDAQ:BFRANASDAQ:KALANASDAQ:NEPTNASDAQ:SLGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$17.38-3.4%$15.49$9.50▼$18.85$1.57B1.61.24 million shs1.11 million shsBFRABiofrontera$2.60$2.95$2.09▼$7.54$73.73M1.0227,512 shs7,263 shsKALAKALA BIO$6.77-1.0%$7.46$5.10▼$19.35$19.09M-1.8526,721 shs9,250 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsSLGLSol-Gel Technologies$0.94+10.5%$1.04$0.79▼$4.20$26.32M1.3329,239 shs4,553 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals-0.55%+11.39%+14.08%+19.61%+78.65%BFRABiofrontera0.00%0.00%0.00%0.00%0.00%KALAKALA BIO-0.73%-6.94%-11.17%-18.43%-56.71%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-60.00%-99.19%SLGLSol-Gel Technologies-9.28%+1.40%-16.81%-24.17%-78.20%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals3.1086 of 5 stars4.52.00.00.03.11.70.6BFRABiofronteraN/AN/AN/AN/AN/AN/AN/AN/AKALAKALA BIO4.0005 of 5 stars3.55.00.04.42.30.80.0NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies3.6306 of 5 stars3.85.00.00.03.31.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals3.00Buy$22.5729.87% UpsideBFRABiofronteraN/AN/AN/AN/AKALAKALA BIO3.00Buy$18.00165.88% UpsideNEPTNeptune Wellness SolutionsN/AN/AN/AN/ASLGLSol-Gel Technologies3.50Strong Buy$8.00746.92% UpsideCurrent Analyst RatingsLatest NEPT, KALA, BFRA, AVDL, and SLGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.003/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.002/6/2024AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$27.96M56.30N/AN/A$0.98 per share17.73BFRABiofrontera$36.19M2.04N/AN/A$0.35 per share7.43KALAKALA BIO$3.89M4.91N/AN/A$2.79 per share2.43NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00SLGLSol-Gel Technologies$1.55M16.98N/AN/A$1.67 per share0.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A20.94N/AN/A-198.06%-84.51%5/2/2024 (Estimated)BFRABiofrontera-$14.88M-$0.73N/A∞N/A-59.44%-93.31%-24.02%N/AKALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)SLGLSol-Gel Technologies-$27.24M-$1.01N/AN/AN/A-1,331.01%-61.52%-53.75%5/10/2024 (Estimated)Latest NEPT, KALA, BFRA, AVDL, and SLGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023SLGLSol-Gel Technologies-$0.16-$0.17-$0.01-$0.17$0.27 million$0.45 million3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ABFRABiofronteraN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A3.643.36BFRABiofrontera0.131.261.13KALAKALA BIO5.106.336.33NEPTNeptune Wellness SolutionsN/A0.230.10SLGLSol-Gel TechnologiesN/A9.109.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%BFRABiofrontera60.07%KALAKALA BIO24.61%NEPTNeptune Wellness Solutions14.44%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.00%BFRABiofronteraN/AKALAKALA BIO13.40%NEPTNeptune Wellness Solutions5.10%SLGLSol-Gel Technologies66.51%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableBFRABiofrontera13828.36 millionN/ANot OptionableKALAKALA BIO432.82 million2.44 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableSLGLSol-Gel Technologies3627.86 million9.33 millionOptionableNEPT, KALA, BFRA, AVDL, and SLGL HeadlinesSourceHeadlineSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in Marchamericanbankingnews.com - April 15 at 5:40 AMSol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Creamglobenewswire.com - April 1 at 7:00 AMSol Gel Technologies Ltd (SLGL)investing.com - March 23 at 11:58 AMSLGL May 2024 2.500 putfinance.yahoo.com - March 16 at 1:25 PMSol-Gel Technologies: Q4 Earnings Insightsbenzinga.com - March 14 at 1:48 PMSol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 14 at 8:47 AMSol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsfinanznachrichten.de - March 14 at 3:47 AMSol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsglobenewswire.com - March 13 at 7:00 AMSol-Gel Technologies Ltd. (SLGL) stock forecast and price targetfinance.yahoo.com - February 28 at 9:43 AMSol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News Summarybenzinga.com - February 22 at 10:05 AMOptimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market Potentialmarkets.businessinsider.com - December 9 at 3:48 AMSol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinanznachrichten.de - November 30 at 6:30 PMSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinance.yahoo.com - November 30 at 8:29 AMSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610finance.yahoo.com - November 28 at 9:36 AMIs Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?finance.yahoo.com - November 20 at 7:19 AMSol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48Mmsn.com - November 9 at 5:31 PMSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 7:27 AMZacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologiesfinance.yahoo.com - October 31 at 9:35 AMIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?finance.yahoo.com - October 10 at 10:05 AMSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 30 at 2:55 PMHC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendationmsn.com - August 15 at 5:07 AMExpert Ratings for Sol-Gel Technologiesmarkets.businessinsider.com - August 11 at 4:26 PMSol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 10 at 2:04 PMSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 9:03 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.BiofronteraNASDAQ:BFRABiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Sol-Gel TechnologiesNASDAQ:SLGLSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.